SHANGHAI, NANJING, CHINA, and SAN JOSE, CA., April 5, 2024. IASO Biotechnology ("IASO Bio"), a biopharmaceutical company dedicated to discovering, developing, manufacturing and commercializing innovat...
SHANGHAI, NANJING, CHINA, AND SAN JOSE, Calif., March 28, 2024 - IASO Bio, a biopharmaceutical company engaged in discovering, developing, manufacturing and marketing innovative cell therapies and ant...
On February 26, 2024, the impactful international academic journal, EMBO Molecular Medicine, published the clinical data of the fully human BCMA targeting autologous CAR-T cell injection (Equecabtagen...
On Jan. 30, 2024, PNAS published the research paper titled "Single-cell analysis of refractory anti-SRP necrotizing myopathy treated with anti-BCMA CAR T-cell therapy." The paper analyzed results usin...
SAN JOSE, CALIFORNIA, SHANGHAI, NANJING, CHINA, AND SEATTLE, WASHINGTON, January 04, 2024 –IASO Biotherapeutics (“IASO Bio”), a biopharmaceutical company engaged in discovering, developing, ma...
SHANGHAI, NANJING, CHINA, and SAN JOSE, Calif., December 11, 2023 – IASO biotechnology (“IASO Bio”), a biopharmaceutical company engaged in discovering, developing, manufacturing and marketing...
82.4% of patients without prior CAR-T achieving Complete Response (CR) or betterSHANGHAI, NANJING, CHINA, AND SAN JOSE, Calif., September 28, 2023 - IASO Bio, a biopharmaceutical company engaged in di...
SHANGHAI, NANJING, CHINA, AND SAN JOSE, Calif., July 3, 2023 - IASO Biotechnology (“IASO Bio”), a clinical-stage biopharmaceutical company engaged in discovering, developing, manufacturing and marke...
The second product of IASO to receive IND approval from the FDASHANGHAI, NANJING, CHINA, AND SAN JOSE , Calif., June 16, 2023 - IASO Biotechnology (“IASO Bio”), a clinical-stage biopharmaceutical co...
SHANGHAI, NANJING, CHINA, AND SAN JOSE , Calif., June 5, 2023 - IASO Biotechnology (“IASO Bio”), a clinical-stage biopharmaceutical company engaged in discovering, developing, and manufacturing inno...